PHVS net incomeFY2025-€175.70M
PHVS net income was -€175.70M for fiscal 2025 (ended Dec 31, 2025), compared with -€134.22M in fiscal 2024.
Pharvaris N.V. (PHVS) financials
For fiscal 2025 (ended Dec 31, 2025), Pharvaris N.V. reported -€175.70M of net income. Figures are in EUR, the currency of its SEC filings.
- Net income, FY2025
- -€175.70M
- Free cash flow, FY2025
- -€137.24M
- EPS, diluted, FY2025
- -€2.97
- Cash
- €291.68M
FY2018FY2025
FY2018FY2025
PHVS revenue and earnings growth
PHVS EPSFY2025-€2.97
PHVS diluted EPS was -€2.97 for fiscal 2025 (ended Dec 31, 2025), compared with -€2.48 in fiscal 2024.
PHVS free cash flowFY2025-€137.24M
PHVS free cash flow was -€137.24M for fiscal 2025 (ended Dec 31, 2025), compared with -€120.67M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Research and development | €124.48M | €98.56M | €65.58M | €57.38M | €35.79M | €19.51M | €5.68M | €3.65M |
| Selling, general and admin | €45.34M | €47.12M | €31.34M | €29.34M | €18.35M | €5.50M | €2.33M | €668.1K |
| Operating income | -€173.71M | -€132.40M | -€99.83M | -€75.65M | -€42.66M | -€26.07M | -€8.03M | -€4.31M |
| Interest expense | - | - | - | €16.1K | €267.5K | €92.5K | €16.9K | €380 |
| Pre-tax income | -€173.71M | -€132.40M | -€99.83M | -€75.65M | -€42.66M | -€26.07M | -€8.03M | -€4.31M |
| Income tax | €1.99M | €1.83M | €1.05M | €679.1K | €70.1K | -€83.3K | €0 | €0 |
| Net income | -€175.70M | -€134.22M | -€100.88M | -€76.33M | -€42.73M | -€25.99M | -€8.03M | -€4.31M |
| EPS, basic | -€2.97 | -€2.48 | -€2.63 | -€2.27 | -€1.40 | - | - | - |
| EPS, diluted | -€2.97 | -€2.48 | -€2.63 | -€2.27 | -€1.40 | - | - | - |
| Diluted shares | 59.2M | 54.0M | 38.4M | 33.6M | 30.4M | 4.8M | 4.8M | 4.8M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | €291.68M | €280.73M | €391.23M | €161.84M | €209.35M | €98.63M | €20.33M | €5.39M |
| Receivables | €4.55M | €2.94M | €1.04M | €382.5K | €700.1K | €569.6K | €210.8K | - |
| Total assets | €301.45M | €291.37M | €398.69M | €167.73M | €212.09M | €101.10M | €20.60M | - |
| Total liabilities | €30.18M | €23.61M | €14.65M | €18.47M | €7.14M | €5.31M | €1.92M | - |
| Shareholders' equity | €271.27M | €267.76M | €384.05M | €149.26M | €204.95M | €95.79M | €18.67M | €4.95M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -€137.07M | -€120.13M | -€93.05M | -€67.16M | -€44.60M | -€21.50M | -€6.68M | -€3.92M |
| Capital expenditures | €164.6K | €538.1K | €90.0K | €124.3K | €130.0K | €43.0K | €13.5K | €0 |
| Free cash flow | -€137.24M | -€120.67M | -€93.14M | -€67.29M | -€44.73M | -€21.54M | -€6.69M | -€3.92M |
| Investing cash flow | -€164.6K | -€538.1K | -€90.0K | -€124.3K | -€130.0K | -€43.0K | -€13.5K | €0 |
| Financing cash flow | €160.61M | €2.68M | €325.39M | €8.65M | €143.67M | €101.20M | €21.63M | €4.51M |
| Stock-based compensation | €19.05M | €16.21M | €10.66M | €11.35M | €8.20M | €1.59M | €116.1K | €100.7K |
Key ratios
Source: XBRL data Pharvaris N.V. files with the SEC, latest filing dated Apr 2, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
PHVS peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| PHVS | - | - | -€175.70M | - | $2.40B |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |
PHVS FAQ
6 questionsIs PHVS profitable?
No. Pharvaris N.V. reported a net loss of €175.70M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does PHVS have?
Pharvaris N.V. reported €291.68M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is PHVS free cash flow?
Pharvaris N.V. generated -€137.24M of free cash flow for fiscal 2025 (ended Dec 31, 2025), which is operating cash flow of -€137.07M less capital expenditures.What is PHVS earnings per share?
Diluted earnings per share were -€2.97 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.When did PHVS last report financial results?
The latest statements here come from Pharvaris N.V.'s 20-F filed on Apr 2, 2026, covering the period ended Dec 31, 2025.Where does this PHVS financial data come from?
Quantisnow builds these statements from the structured XBRL data Pharvaris N.V. files with the SEC. It is provided for information only and is not investment advice.